High Vista Strategies LLC Relmada Therapeutics, Inc. Transaction History

High Vista Strategies LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$2.17 - $35.84 $8,167 - $134,901	-3,764 Reduced 12.52%	26,299 $91,000
Q3 2022 Nov 14, 2022	BUY	$18.3 - $37.02 $10,431 - $21,101	570 Added 1.93%	30,063 $1.11 Million
Q2 2022 Aug 15, 2022	BUY	$16.5 - $30.34 $133,848 - $246,118	8,112 Added 37.94%	29,493 $560,000
Q1 2022 May 16, 2022	BUY	$16.72 - $26.99 $357,490 - $577,073	21,381 New	21,381 $577,000
Q1 2021 May 17, 2021	SELL	$31.52 - $39.28 $707,624 - $881,836	-22,450 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$29.88 - $39.8 $295,363 - $393,423	9,885 Added 78.67%	22,450 $720,000
Q3 2020 Nov 16, 2020	BUY	$34.42 - $43.78 $98,854 - $125,736	2,872 Added 29.63%	12,565 $473,000
Q2 2020 Aug 14, 2020	BUY	$31.59 - $49.98 $306,201 - $484,456	9,693 New	9,693 $434,000

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of High Vista Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on High Vista Strategies LLC with notifications on news.